Gladiator Uc: Etrasimod Versus Placebo For The Treatment Of Moderately Active Ulcerative Colitis
Posted Date: Sep 21, 2021
- Investigator: Loren Brook
- Type of Study: Drug
This study is to assess the efficacy of Etrasimod on clinical remission in subjects with moderately active ulcerative colitis (UC) after 12 weeks of treatment.
Age 18-80. Ability To Provide Written Informed Consent And To Be Compliant With The Schedule Of Protocol Assessments. Diagnosed With Ulcerative Colitis At Least 3 Months Prior To Screening.
Ulcerative Colitis, Uc
For More Information: